On this page
ALG9
ALG9 alpha-1,2-mannosyltransferase
The ALG9 gene provides instructions for making an enzyme called alpha-1,2-mannosyltransferase, which plays a key role in the process of N-linked glycosylation, essential for proper protein function. The ALG9 gene is vital for N-linked glycosylation, a modification process where sugar chains are attached to proteins, influencing their structure and function.
ALG9 is located on the long (q) arm of chromosome 11, at band 11q23.1. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 11 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The ALG9 gene encodes an enzyme known as alpha-1,2-mannosyltransferase. This enzyme is fundamentally involved in N-linked glycosylation, a critical cellular pathway responsible for attaching complex sugar structures (glycans) to specific proteins. These glycosylated proteins perform diverse roles, including cell signalling, immune response, and structural support within the body.
Disruptions to the ALG9 gene, particularly specific genetic variants, can impair the proper functioning of this enzyme. Such impairment often results in a group of conditions collectively known as congenital disorders of glycosylation (CDG). These disorders are characterised by developmental and functional abnormalities affecting multiple organ systems due to improperly glycosylated proteins.
What the gene does
The ALG9 gene product, alpha-1,2-mannosyltransferase, functions within the endoplasmic reticulum, an organelle critical for protein synthesis and modification. Its specific enzymatic role is to catalyse the addition of a mannose sugar molecule to a growing oligosaccharide chain. This step is crucial in the lipid-linked oligosaccharide pathway, which serves as the donor for N-linked glycosylation.
N-linked glycosylation itself is a complex, multi-step process where a preformed oligosaccharide is transferred to specific asparagine residues on nascent proteins. This modification is essential for protein folding, stability, trafficking, and overall biological activity. The mannose trimming and addition steps, mediated by enzymes like ALG9, ensure the correct structure of the glycan. Defects in ALG9 can lead to incomplete or incorrectly formed oligosaccharides, subsequently affecting a wide array of glycoproteins and their associated biological functions throughout the body.
Video: Genetics 101
Chromosome location
The ALG9 gene is located on chromosome 11, specifically at position 11q23.1. This indicates its precise physical address within the human genome. Genes reside on chromosomes, which are tightly packed structures of DNA. The 'q' refers to the long arm of the chromosome, and '23.1' denotes the specific band where the gene can be found.
Protein structure
The ALG9 gene encodes a protein composed of 611 amino acids. Structural analysis has identified a disordered region at the protein's amino terminus, encompassing residues 1 through 23. Disordered regions lack a fixed three-dimensional structure and remain flexible under physiological conditions. Such regions often serve important functional roles despite their lack of stable folding. They may facilitate protein-protein interactions, enable regulatory modifications, or allow the protein to adopt different conformations in response to binding partners. The presence of this N-terminal disordered region in ALG9 suggests it may contribute to the enzyme's regulation, localisation within the endoplasmic reticulum, or interaction with other components of the glycosylation machinery. These flexible segments can act as molecular switches or linkers, providing the protein with adaptability in its cellular environment.
Key variants
Genetic variants in the ALG9 gene can alter the normal function of the alpha-1,2-mannosyltransferase enzyme. These changes can range from single nucleotide substitutions to larger deletions or insertions within the gene's DNA sequence. When such variants are pathogenic, they typically lead to a reduction or complete loss of the enzyme's activity, thereby disrupting the crucial N-linked glycosylation pathway. The specific impact of a variant often depends on its location within the gene and how severely it affects the protein's structure and function.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1225del | p.Arg409fs | Pathogenic/Likely pathogenic | ★★☆☆ | ALG9-associated autosomal dominant polycystic kidney disease |
c.427C>T | p.Arg143Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Gillessen-Kaesbach-Nishimura syndrome |
c.566-1G>A | - | Pathogenic/Likely pathogenic | ★★☆☆ | ALG9 congenital disorder of glycosylation |
c.744G>A | p.Trp248Ter | Pathogenic/Likely pathogenic | ★★☆☆ | ALG9 congenital disorder of glycosylation |
c.860A>G | p.Tyr287Cys | Pathogenic/Likely pathogenic | ★★☆☆ | Gillessen-Kaesbach-Nishimura syndrome |
c.100C>T | p.Arg34Ter | Pathogenic | ★☆☆☆ | ALG9 congenital disorder of glycosylation |
c.1163_1164del | p.Ser388fs | Pathogenic | ★☆☆☆ | ALG9-related disorder |
c.1219C>T | p.Arg407Ter | Pathogenic | ★☆☆☆ | ALG9-associated autosomal dominant polycystic kidney disease |
c.126del | p.Thr43fs | Pathogenic | ★☆☆☆ | ALG9 congenital disorder of glycosylation |
c.1296dup | p.Phe433fs | Pathogenic | ★☆☆☆ | ALG9 congenital disorder of glycosylation |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Variants in the ALG9 gene are primarily associated with a class of inherited metabolic disorders known as congenital disorders of glycosylation (CDG). These conditions arise from defects in the synthesis or attachment of glycans to proteins or lipids. Given ALG9's critical role in N-linked glycosylation, pathogenic variants in this gene specifically impede the proper formation of protein-linked sugar chains, leading to a type of CDG. These disorders can manifest with a wide spectrum of clinical symptoms affecting multiple organ systems.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic ALG9 variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
In the UK, the ALG9 gene is recognised within several NHS Genomic Medicine Service clinical panels, indicating its significance in diagnosing a range of inherited conditions. It is listed in panels for Congenital disorders of glycosylation, Cystic kidney disease, DDG2P (Developmental Disorders Genotype-Phenotype Database), Early onset or syndromic epilepsy (R59), Foetal anomalies (R21), Intellectual disability (R29), Likely inborn error of metabolism (R98), Skeletal dysplasia (R104), and Undiagnosed metabolic disorders. This widespread inclusion reflects the gene's established role in these conditions and its utility in genetic testing.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
No specific lifestyle interventions have been shown to modify the underlying genetic mechanisms of ALG9-related conditions. General health measures such as balanced nutrition and regular physical activity support overall well-being but are not targeted treatments for these genetic disorders.
Supplement considerations
No specific dietary supplements have been scientifically proven to prevent, treat, or alleviate symptoms of conditions directly caused by ALG9 gene variants. Individuals with an ALG9-related condition should always consult a qualified healthcare professional before considering any supplement use. Professional medical advice is essential to avoid potential interactions with medications or unproven benefits.
Frequently asked questions
What is the main function of the ALG9 gene?
The ALG9 gene provides instructions for creating an enzyme called alpha-1,2-mannosyltransferase, which is crucial for N-linked glycosylation, a process that attaches sugar chains to proteins.
What happens if there are variants in the ALG9 gene?
Variants in the ALG9 gene can disrupt the normal function of the alpha-1,2-mannosyltransferase enzyme, leading to errors in N-linked glycosylation and potentially causing congenital disorders of glycosylation (CDG).
What are congenital disorders of glycosylation (CDG)?
Congenital disorders of glycosylation are a group of inherited metabolic conditions caused by defects in the synthesis pathways of glycans, which are sugar chains essential for the proper function of many proteins and lipids.
How is ALG9 relevant for carrier screening?
The ALG9 gene may be included in carrier screening panels because it is associated with autosomal recessive congenital disorders of glycosylation. Carrier screening helps identify individuals who carry a copy of a pathogenic variant but do not show symptoms themselves, allowing them to understand potential risks for their offspring.
Can diet or lifestyle changes affect ALG9-related conditions?
Currently, there is no scientific evidence that specific diet or lifestyle changes can prevent or cure conditions directly caused by ALG9 gene variants. General healthy living is always recommended, but medical management should be discussed with a healthcare professional.